SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
EYPT

EyePoint, Inc. (EYPT)

NASDAQ: EYPT · USD
Healthcare · Biotechnology
$0.30-$0.01 (-3.80%)
 
Market cap
$33.7M
Insider Score
Analyst consensus
Market Cap$33.67M-97.7%
Revenue (ttm)$2.58M
Net Income-$342.52M
EPS-$3.97
Shares Out113.78M
PE Ration/a
Forward PE-0.18
Dividendn/a
Ex-Dividend Daten/a
Volume4,575,241
Open$0.30
Previous Close$0.31
Day's Range$0.29 - $0.32
52-Week Range$0.28 - $19.11
Beta1.90
AnalystsHold
Price Target$8.31(+2709.23%)
Earnings DateNov 12, 2026

About EYPT

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Address
480 Pleasant Street, Watertown, MA, 02472, United States
Market Cap
34 million
Employees
214
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$52.26K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Hold
1 Buy6 Hold1 SellAvg target $10.63 (+3355.8%)

8 firms rating EYPT in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-3.23%
5 Days
-25.00%
1 Month
-31.82%
6 Months
-97.46%
1 Year
-97.72%

$EYPT stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in EYPT holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by EYPT's directors and management

Net Shares Purchased by Insiders−20k−10k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

EYPT Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New EYPT patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to EYPT from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from EYPT’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
6.29
Analyst Ratings
32% of score
60
News & Sentiment
20% of score
35

News check: Q3 earnings beat on revenue but company reported net loss and significant workforce reduction linked to Wet AMD setback, indicating material challenges ahead.

Recent Insider Activity

Buys
2
Sells
5
Buy Value
$52.26K
Distinct Buyers
2

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

XPHState Street SPDR S&P Pharmaceuticals ETF0.07%
QQQSInvesco NASDAQ Future Gen 200 ETF0.04%
BBCVirtus Biotech Clinical Trials ETF0.02%
PILLDirexion Daily Pharmaceutical & Medical Bull 3X ETF0.01%
IHEiShares U.S. Pharmaceuticals ETF0.01%
VHTVanguard Health Care ETF0.00%
IBBQInvesco Nasdaq Biotechnology ETF0.00%
BIBProShares Ultra Nasdaq Biotechnology0.00%
FHLCFidelity MSCI Health Care Index ETF0.00%

Weight is the stock’s share of each fund’s holdings.